In this study, about 28.2% of the elderly patients with NSCLC harboring drug-sensitive EGFR mutations underwent EGFR-TKI rechallenge after first-line EGFR-TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.